Benjamin Joseph Littler

This inventor holds 34 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 12 EPO patents, primarily in Cystic Fibrosis Modulators. Top assignees: Vertex Pharmaceuticals, Inc., Biomed Valley Discoveries, Inc., Helsinn Therapeutics (u.s.), Inc.. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benjamin Joseph Littler. Retrieved from https://idiyas.com/inventor/benjamin-joseph-littler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 6)

% Patents Active = 94.1

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 7.9

ph-index = 15

Forward Citations = 718(Granted Patents)

Location History:

San Diego, CA (US) (2009 - 2018)
Carlsbad, CA (US) (2013 - 2023)

Company Filing History:

31 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

5 out of 42

Biomed Valley Discoveries, Inc.

patents

2 out of 9

Helsinn Therapeutics (u.s.), Inc.

patents

4. 1 out of 70

Helsinn Healthcare Sa

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Cystic Fibrosis

ATR Inhibitors

Pyridone Amides

Modulators

Sodium Channels

Biaryl Ureas

Crystalline Forms

Cycloalkylcarboxamido

Indole Compounds

Pyrrolidine Compounds

ATP-Binding Cassette Transporters

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12415798 - Processes for making modulators of cystic fibrosis transmembrane conductance regulator (2025-09-16),

2. 12187698 - Crystalline forms of CHClNO (2025-01-07),

3. 12122788 - Process of making CFTR modulators (2024-10-22),

4. 11773119 - Prodrugs of pyridone amides useful as modulators of sodium channels (2023-10-03),

5. 11584761 - Process of making CFTR modulators (2023-02-21),

6. 11465985 - Processes for making modulators of cystic fibrosis transmembrane conductance regulator (2022-10-11),

7. 11434201 - Processes for preparing pyrrolidine compounds (2022-09-06),

8. 11390600 - Crystalline forms of CHClNO (2022-07-19),

9. 10822331 - Processes for preparing ATR inhibitors (2020-11-03),

10. 10787472 - Prodrugs of pyridone amides useful as modulators of sodium channels (2020-09-29),

11. 10738027 - Crystalline forms of CHClNO (2020-08-11),

12. 10253054 - Prodrugs of pyridone amides useful as modulators of sodium channels (2019-04-09),

13. 10208027 - Processes for preparing ATR inhibitors (2019-02-19),

14. 10183927 - [object Object] (2019-01-22),

15. 10071979 - Process of producing cycloalkylcarboxamido-indole compounds (2018-09-11),

Title: Innovations and Contributions of Benjamin Joseph Littler

Introduction

Benjamin Joseph Littler, based in Carlsbad, California, is an accomplished inventor recognized for his notable contributions in the field of pharmaceuticals. With a remarkable portfolio of 33 patents, Littler's work focuses on innovative compounds that play a crucial role in the treatment of various diseases, including cancer.

Latest Patents

Among his recent innovations, Littler has developed crystalline forms of CHClNO, which are essential for creating effective pharmaceutical compositions. These compositions are designed for the treatment of cancer, demonstrating his commitment to advancing medical science. Additionally, he has disclosed processes for synthesizing CFTR modulators and their pharmaceutically acceptable salts, further contributing to the treatment options available for patients.

Career Highlights

Littler has had an impressive career, having worked with esteemed companies such as Vertex Pharmaceuticals, Inc. and Biomed Valley Discoveries, Inc. His work in these organizations has significantly advanced the development of therapeutic solutions in the pharmaceutical industry.

Collaborations

Throughout his career, Benjamin has collaborated with talented professionals, including Robert Michael Hughes and Ali Keshavarz-Shokri. These partnerships have fostered innovation and enabled the successful development and patenting of critical pharmaceutical inventions.

Conclusion

Benjamin Joseph Littler's dedication to innovation in pharmaceuticals is evident through his extensive patent portfolio and successful collaborations. His contributions continue to impact the treatment landscape, providing hope for patients facing challenging health conditions. His work exemplifies the importance of research and innovation in the quest for effective medical therapies.

Profile summary based on public USPTO records.